Bio-Rad Laboratories (NYSE:BIO.B) Sets New 1-Year High – Time to Buy?

Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO.B) reached a new 52-week high during mid-day trading on Tuesday. The stock traded as high as $379.50 and last traded at $379.50, with a volume of 204 shares. The stock had previously closed at $365.08.

Bio-Rad Laboratories Stock Up 3.9%

The business has a 50-day moving average price of $363.13 and a 200-day moving average price of $309.70. The firm has a market capitalization of $10.15 billion, a PE ratio of 46.00 and a beta of 0.96. The company has a quick ratio of 2.33, a current ratio of 3.14 and a debt-to-equity ratio of 0.11.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc (NYSE: BIO.B) develops, manufactures and markets products and systems used in life science research and clinical diagnostics. The company serves academic, pharmaceutical, biotechnology, industrial and healthcare customers with laboratory instruments, reagents, consumables, software and related services.

Its life science portfolio includes technologies for genomics, digital PCR, protein analysis, chromatography, electrophoresis, cell biology and imaging. Bio-Rad’s clinical diagnostics business provides systems and reagents used in areas such as diabetes monitoring, blood typing, quality control, infectious disease testing and autoimmune diagnostics.

Founded in 1952 by David and Alice Schwartz, Bio-Rad is headquartered in Hercules, California, and serves customers through operations and distribution networks in North America, Europe, Asia-Pacific and other international markets.